R&D Will cell and gene therapies disrupt reimbursement? Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people with rare diseases and cancers – but they could also mean healthcare systems
Digital Defining the digital therapeutics opportunity Once the stuff of science fiction, an emerging category of medicine is set to be increasingly influential in healthcare.
Digital Company profile: Evidera Data disruption and applying ‘enabled intelligence’ to convert the promise shown in clinical trials into real-world success.
Digital What future for pharma in a digital world? Heads of innovation, communication and digital strategy in pharma reflected at Frontiers Health 2018 on the implications of technological changes.
Digital Pharma in the age of acceleration Syneos Health tracks the future paths for healthcare technology to identify what will be truly disruptive for the pharmaceutical industry.
R&D Opening doors in pharmaceutical development Evidera surveys the adoption of machine learning by the pharmaceutical industry and looks at how it can increase R&D efficiencies.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.